Journal of Nuclear Medicine: 57 (12)

December 1, 2016; Volume 57,Issue 12

Cover image

²²⁵Ac-PSMA-617 has shown high potential to benefit patients with metastatic castration-resistant prostate cancer who are in a clinically critical situation. See page 1941.

In this issue

Issue highlights

Clinically Approved Nanoparticle Imaging Agents
In Vivo Imaging of Human ¹¹C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses
Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸F-FDG
Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to